Clinical Trial, BeNeLux

Prosensa Publishes DMD study results in NEJM


Prosensa NV and researchers from Leiden University Medical Center (LUMC) under Prosensa's scientific advisor Prof. Gertjan van Ommen have published results from a Phase I clinical study with the 2-’O-methyl antisense compound PRO051 in four children (aged 10-13) with Duchenne Muscular Dystrophy (DMD) (N Engl J Med. 357(26):2677-86). Intramuscular injection of a single 80 mg shot of the compound, which is able to correct the open reading frame of the DMD gene by exon skipping and thus to restore dystrophin expression, was not associated with clinical adverse reactions, according to Prosensa. Additionally, PRO051 restored dystrophin expression in the treated muscle fibers of all four patients, who had been selected on the basis of their mutational status, muscle condition, and positive exon-skipping response to PRO051 in vitro. The compound will be suitable for 13% of all DMD patients (DMD incidence

1: 3,500), because it can treat a cluster of DMD mutations.

Miscellaneous, BeNeLux


Brussels – UCB Group will initiate an additional short-term clinical study of CimziaTM (certolizumab pegol), its pegylated antibody directed against Tumour Necrosis Factor (TNF), to confirm the induction of clinical response in...

Miscellaneous, UK


London – The European Medicines agency has recommended approval for Bristol-Myers Squibbs IgG1-CTLA4 binding protein Abatacept (Orencia) in combination with metho­trexate as a treatment for rheumatoid arthritis. The antibody...



Looking at the performance of European biotech in 2007, it has turned out that both important US biotech indices, the Nasdaq Biotech index (+6.6%) and the AMEX Biotech index (+10.2%), outperformed our WestLB EU Biotech index...

Clinical Trial, France


Nautilus Biotech (Evry, France) has initiated a Phase I clinical trial for subcutaneous Belerofon® (SC), its mutated human Interferon (IFN) alpha designed to have lower sensitivity to protease-mediated degradation than...

Clinical Trial, Switzerland


A Novartis AG (Basel, Switzerland) has been given the green light from the US Food and Drug Administration (FDA) for its direct renin inhibitor Tekturna® (aliskiren) for the treatment of high blood pressure. The once-per-day...

Clinical Trial, Switzerland


Roche AG (Basel, Switzerland) has been given market approval from the European Commission for its blockbuster VEGF inhibitor Avastin (bevacizumab) as a first-line treatment in combination with the chemotherapeutic paclitaxel for...

Clinical Trial, SwedenSweden


Resistentia Pharmaceuticals AB (Uppsala, Sweden) has initiated a Phase II dose-escalation study of its anti-IgE immunotherapy, RP01, as a treatment for allergic asthma in mid-April. RP01 induced significant production of...



Germany currently holds the European Council presidency, which is why the German capital has been the site of choice for many European meetings and activities of late. In a recent Berlin meeting, Commission president José Manuel...



Dr. Marc Cluzel (1) is the new Senior Vice President, Science and Medical Affairs at Sanofi-Aventis S.A. Cluzel joined the Montpellier-based Sanofi Recherche in 1991, gaining promotions until becoming Senior Vice President,...



Dr. Koenraad Blot (2), will join Elbion NV´s management team as Chief Medical Officer and is returning to Belgium after many years of managing experiences abroad. Previously, Blot has worked as an Executive Director Clinical...

Displaying results 791 to 800 out of 1982

< Previous 791-800 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • THERAMETRICS0.08 CHF14.29%
  • MEDIGENE10.96 EUR4.88%
  • EVOLVA1.58 CHF3.27%


  • BIOTEST71.00 EUR-3.92%
  • SYNGENTA314.40 CHF-3.65%
  • 4SC5.03 EUR-3.27%


  • 4SC5.03 EUR293.0%
  • WILEX4.33 EUR51.4%
  • SARTORIUS151.00 EUR21.2%


  • CYTOS1.01 CHF-29.4%
  • BIOTEST71.00 EUR-26.9%
  • BIOFRONTERA2.30 EUR-11.2%


  • SANTHERA96.45 CHF2323.4%
  • WILEX4.33 EUR397.7%
  • CYTOS1.01 CHF359.1%


  • MOLOGEN4.94 EUR-55.2%
  • BIOFRONTERA2.30 EUR-27.7%
  • EPIGENOMICS5.60 EUR-20.0%

No liability assumed, Date: 04.05.2015

Current issue

All issues